[Solved] Is there a chance of psychosis after I have used psychedelics?

The chance of a healthy person developing psychosis due to psychedelics is very small. However, psychedelics can cause temporary effects that resemble symptoms of psychosis, such as hallucinations and delusions. We sometimes refer to these trips as mini-psychoses. A large population study from 2015 found no association between psychedelic use and the likelihood of psychological distress. People who used psychedelics were not at a higher risk of psychosis than others. Generally speaking, however, it can be stated that the use of substances such as MDMA, marijuana, LSD, Ayahuasca, and psilocybin can give a person on the verge of psychosis the final push.

Classic psychedelics such as LSD, psilocybin (magic mushrooms), and DMT have been linked to the risk of psychosis for decades. As a precaution, individuals with schizophrenia or an increased family risk are often excluded from psychedelic research or therapy. However, the question remains how significant the risk of psychosis is for people without known personal or family predisposition for mental disorders (such as schizophrenia or bipolar disorder) that use psychedelics. In this report, we examine findings from large-scale scientific studies – with control groups – that the incidence of psychotic episodes or investigate long-term psychosis after classical psychedelic use in this low-risk group. We discuss the research methods, key results, and conclusions regarding the absolute and relative risk.

Research methods in large-scale studies

To determine the effect of psychedelics on the risk of psychosis, researchers have used various approaches:

1. Cross-sectional population studies: In this context, large samples of the population are surveyed regarding their drug use and mental health. An example is an analysis of over 130,000 American adults (2001–2004) comparing psychological outcomes in people who had ever used psychedelics with non-users. Such studies statistically control for factors such as age, sex, other drugs, and trauma to obtain a clear picture of the relationship.

2. Longitudinal cohort studies: This involves following people over time. A recent study, for example, followed approximately 9,700 representative adults in the US and UK for two months to see if new psychedelic users developed more psychotic symptoms compared to non-users. There are also twin studies done, in which identical twins are compared (one twin used a psychedelic, the other did not) to control for genetic and environmental factors.

3. Retrospective cohort studies with medical data: A large-scale Canadian study linked medical records of 9.24 million persons (without a history of psychosis) over 13 years. In this study, people who had ever ended up in the emergency room after using hallucinogens (classic psychedelics) were compared with matched individuals without such an incident. This type of study focuses particularly on serious cases (such as acute hallucinogen-induced psychosis) and the later development of schizophrenia spectrum disorders.

4. Meta-analyses and systematic reviews: To obtain a broader picture, some studies combine data from dozens of studies. For example, Sabé et al. (2025) conducted a meta-analysis of 131 publications (including RCTs, cohort studies, and case reports) to incidence of psychedelic-induced psychosis to estimate.

Through these diverse methods – involving control groups and often large sample sizes – we can paint a reliable picture of the risk of psychosis after psychedelic use in individuals. without known vulnerability.

Findings from epidemiological studies

No increased risk of psychosis in the general population

Large population surveys take no indication that psychedelics increase the risk of mental disorders in healthy users. In the aforementioned American survey (NSDUH, >130,000 respondents), it was reported 13,4% to have ever used a classic psychedelic. The researchers found no significant associations between ever using psychedelics and the occurrence of mental health problems, including psychotic disorders. In fact, at some points, psychedelic users had lower chances of mental health problems than non-users. For example, in this analysis, the chance of a diagnosis was non-affective psychosis among psychedelic users approximately half of that among non-users (aOR ~0.5, 95% CI 0.3–0.9) when adjusted for other factors. In other words: people who had ever used LSD, psilocybin, or mescaline were not more often psychotic or psychiatrically ill than people who never did that – the use of psychedelics turned out no independent risk factor for psychological problems. This finding is consistent with the fact that documented cases of long-term psychosis following exclusive psychedelic use are extremely rare. The literature shows, for example, that there are only very little Case descriptions exist of persistent psychiatric symptoms after the use of psilocybin or mescaline, and that reports of psychological damage caused by peyote were almost always associated with all existing mental disorders.

Longitudinal studies: role of predisposition

Prospective research also shows no increased risk of psychosis for average users, except in the case of a latent one. vulnerability. Honk et al. (2024) followed thousands of adults in the US and the UK for two months. They observed no increase of the number of psychotic symptoms in those who took psychedelics during that period compared with those who did not, as long as there was no indication of a psychological predisposition. An effect emerged only in specific groups: among participants with a personal or familial history of bipolar disorder the number of psychotic experiences increased well slightly increased after psychedelics, whereas in participants with a personal history of psychotic disorder, the number of symptoms actually decreased. The authors interpreted this cautiously: psychedelic use primarily affects psychotic symptoms in people with a personal or family history of psychotic or mood disorders, and not in the average user.

A similar message comes from a Swedish twin study (Simonsson et al., 2024) among adolescent twins. Without correction, teenagers who had ever used a psychedelic appeared to be slightly more to report psychotic or manic symptoms more than non-users. But as soon as controlled for the use of other substances, this association reversed: psychedelic users then had fewer psychotic (and manic) symptoms than comparable non-users. Crucially, the comparison between identical twins showed no difference in psychotic symptoms – the twin who had tried psychedelics was not sicker (and earlier something better) than the genetically identical half that did not use psychedelics. This suggests that underlying genetic or environmental factors (such as a propensity for substance use) were more likely the cause of the small rough difference, and not the psychedelic substance itself. In short, longitudinal research confirms that for humans without known aptitude the use of LSD or psilocybin is not accompanied by a measurable increase in psychotic symptoms or disorders. Any adverse effects manifest primarily in those with a latent sensitivity that can be stimulated by the substance.

Incidence of psychosis after psychedelics

How often does psychedelic use actually lead to a clinical psychosis? Large-scale data point to a extremely low incidence among healthy users. A recent meta-analysis (Sabé et al., 2025) combined data from dozens of studies (ranging from population studies to clinical trials). This showed that the lifetime incidence of a psychedelic-induced psychosis in general population studies only ~0,002% was – this corresponds to approximately 2 cases per 100,000 users. In clinical settings, the figures are slightly higher but still low: in open-label or uncontrolled trials ~0.2%, and in randomized placebo-controlled trials approximately 0,6% of the participants developed a (usually short-lived) psychosis. For context: these trials generally exclude individuals with known high risk, so 0.6% concerns isolated unexpected reactions in seemingly mentally stable subjects.

It is important that if there well if a psychotic episode occurs after the use of a psychedelic, this incident must be taken seriously. The meta-analysis made it clear that a small proportion of such cases eventually develop into a chronic disorder: approximately 13% of the people who developed psychedelic-induced psychosis were later diagnosed with schizophrenia. This is consistent with findings from the retrospective cohort in Canada: among the more than 9 million people without a history of psychosis, a small group (0.1%) had a acute crisis after hallucinogenic use that required a hospital visit. Within three years of such an incident, approximately developed 4% of this group a schizophrenia spectrum disorder, compared to only 0.15% in the general population without such an incident. This means that the relative The chance of developing schizophrenia after a severe psychedelic incident was approximately 21 times higher than in someone who had not experienced such an episode. After correcting for existing substance abuse and mental health problems, the hazard ratio remained ~3.5, indicating that a hallucinogen-related psychosis incident is in itself a substantial signal of risk. Although this sounds drastic, it must be emphasized that this concerns exceptional cases (often described as “hallucinogen-induced psychosis” in the emergency department). Such acute reactions may point to a hidden vulnerability who is triggered by the substance. In practice, this concerns a very small proportion of all psychedelic users – but if If someone without a clear history experiences a psychotic episode after use, that person deserves close follow-up care, because the risk of a long-term psychotic disorder is then significantly higher.

Conclusions: absolute and relative risk

In conclusion, for persons without a known predisposition to psychosis or bipolar disorder, the absolute risk of developing psychosis after classical psychedelic use appears extremely low. Epidemiological data suggest no increase in psychotic disorders compared with non-users – large population studies find no increased risk (odds ratios around or even below 1). In absolute terms, persistent psychosis after psychedelics is very rare (on the order of a few cases per hundred thousand users). The relative risk compared to people who never use psychedelics is therefore negligibly small in this group. Even in carefully designed comparisons with control groups (in longitudinal designs and twin studies), there is no A clear causal effect of psychedelics on the occurrence of psychotic symptoms in healthy individuals has emerged.

At the same time, the data show that psychedelics incidentally a psychotic episode can trigger. This particularly affects people with undiagnosed risk factors – although they have no known history, a latent genetic vulnerability could play a role. In such cases (for example, an acute “bad trip” with psychosis requiring medical help) it rises absolute risk of a permanent psychotic disorder for that person to a few percent. The relative The risk in that subgroup is much higher than normal (multiply increased compared to someone without such an episode). This underscores that caution remains warranted: psychosis after psychedelics is exceptional, but if it occurs, the prognostic significance is considerable.

In summary: For the average person without Regarding psychological vulnerability, according to large-scale research, there is no evidence that the use of LSD, psilocybin, or similar classic psychedelics leads to an increased risk of long-term psychosis. The absolute risk of developing a schizophrenia-like disorder after use is extremely low – at the population level, there is around zero difference compared to non-users. Relatively speaking, someone without a predisposition who uses a psychedelic is not more likely to become psychotic than someone who does not. Only in extremely rare cases does a persistent psychosis develop, often associated with hidden susceptibility. Such cases constitute the exception that proves the rule: classic psychedelics do not carry a measurably increased risk of psychosis in the vast majority of stable users.

Sources: The above findings are based on peer-reviewed studies, including population surveys, longitudinal cohort and twin studies, meta-analyses, and large-scale medical database analyses, which collectively paint a consistent picture of the limited psychosis risk of classic psychedelics in individuals without pre-existing vulnerability.

Psychedelics and psychosis are sometimes linked. What is often overlooked is that individuals with psychotic tendencies often seek solutions through self-medication and therefore turn to substances such as cannabis and truffles. In that case, one cannot conclude that psychedelics trigger psychosis, but rather that people prone to psychosis are more inclined to use psychedelics.

In short, it is unlikely that psychedelics cause psychosis in healthy people.

It does not appear that psychedelics can cause you to become psychotic overnight, but they can push some people over the edge if they are already on the verge of it. Therefore, caution is advised for people with a predisposition to psychosis. If you experience frequent delusions, you should be careful and have yourself screened by a doctor first.

This is actually a question that many people struggle with, and it is good that you are wondering about it. The short answer is that the risk for someone without known sensitivity is extremely small, but I will provide some more context.

The reason psychedelics are always associated with psychosis likely lies in the fact that they can induce intense psychological experiences. Hallucinations, altered perception, and spiritual insights feel unexpected to many people, and they may superficially resemble psychotic symptoms. However, there is a crucial difference here: with psychosis, a person loses contact with reality and perceives things as real, whereas during a trip, people usually know they are under the influence. That reflection is very important.

What science shows is that in large population studies, people who have used psychedelics do not become psychotic more often than people who never have. In fact, in some studies, the percentages were even slightly lower. This is supplementary research in which hundreds of thousands of people have been followed, so there is a solid data basis for it.

It also helps to understand that psychosis has multiple causes. It can be hereditary, caused by trauma, sleep deprivation, or other stressful circumstances. Drugs can sometimes be a trigger for someone who is already sensitive to them, but they do not simply create something out of nowhere that doesn't affect them. That is why people with a family history of psychosis need to be more cautious – not because psychedelics are necessarily dangerous, but because their underlying vulnerability is greater.

You say that there are no known cases in your family and that you do not know if you are susceptible. That means you are actually in the lowest risk category. You cannot rule out everything in life because of theoretical risks – that would mean you also have to avoid certain experiences that are likely to cause much more harm, such as chronic stress or sleep deprivation.

What I would say is: take care of yourself before, during, and after any potential experience. Ensure you are in a safe environment with people you trust. Avoid psychedelics if you already suffer from anxious thoughts, paranoia, or other psychological symptoms. And if, after an experience, you notice that you are developing delusions that do not go away after sobering up, take that seriously and seek professional help – not because psychosis is likely, but because caution is advised.

All in all, it seems more like a theoretical risk than a practical problem for your situation.